Posted by Michael Wonder on 06 Sep 2024
ICER publishes evidence report on treatments for transthyretin amyloid cardiomyopathy
5 September 2024 - Current evidence suggests that tafamidis and acoramidis provide a net health benefit when compared to no disease-specific therapy; these treatments would achieve common thresholds for cost effectiveness if priced between $13,600 - $39,000/year
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness of tafamidis (Vyndamax/Vyndaqel, Pfizer), acoramidis (BridgeBio Pharma) and vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of transthyretin amyloid cardiomyopathy.
